<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765921</url>
  </required_header>
  <id_info>
    <org_study_id>07-06-040</org_study_id>
    <secondary_id>FVF4384s</secondary_id>
    <nct_id>NCT00765921</nct_id>
  </id_info>
  <brief_title>Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma</brief_title>
  <official_title>A Phase I Single Center Study of Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the safety and tolerability of the anti-VEGF
      (vascular endothelial cell growth factor) treatment, ranibizumab, in combination with proton
      beam irradiation for the treatment of choroidal melanoma by determining the incidence and
      severity of ocular adverse events. Systemic adverse events will also be evaluated. A
      secondary objective is to assess the efficacy of ranibizumab in reducing ocular complications
      that can occur after irradiation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence and severity of ocular adverse events and systemic adverse events</measure>
    <time_frame>12 months and 24 months after initial treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of radiation-induced complications, vision loss and eye loss</measure>
    <time_frame>12 months and 24 months after initial treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Choroidal Melanoma</condition>
  <arm_group>
    <arm_group_label>1.0 mg ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg intravitreal injection given bi-monthly for 22 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg intravitreal injection given bi-monthly for 22 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).</description>
    <arm_group_label>1.0 mg ranibizumab</arm_group_label>
    <arm_group_label>0.5 mg ranibizumab</arm_group_label>
    <other_name>rhuFab</other_name>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed choroidal melanoma undergoing proton therapy

          -  Tumors &gt;15 mm in largest diameter and/or &gt;5 mm in height

          -  Tumors ≤ 15 mm in largest diameter and ≤ 5 mm in height located ≤ 3 mm from optic disc
             and/or macula, with best-corrected visual acuity 20/100 or better in study eye

        Exclusion Criteria:

          -  History of prior treatment for choroidal melanoma

          -  Pregnancy or lactation

          -  Presence of diabetic retinopathy

          -  History of retinal vascular occlusion or other retinal vascular disease

          -  Active ocular inflammation or history of uveitis in either eye

          -  History of uncontrolled glaucoma (defined as intraocular pressure &gt;30mmHg despite
             treatment with anti-glaucoma medication) or filtering surgery in the study eye

          -  Previous intravitreal injections of Avastin® in the study eye or in the non-study eye
             within 30 days.

          -  Concurrent use of systemic anti-VEGF therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivana Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear Infirmary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts Eye &amp; Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2008</study_first_submitted>
  <study_first_submitted_qc>October 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2008</study_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma, neovascular</keyword>
  <keyword>macular edema</keyword>
  <keyword>eye enucleation</keyword>
  <keyword>antibodies, monoclonal</keyword>
  <keyword>radiation oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

